SWOG - S2209- VRD-Lite Vs DRd-R Vs DRd-DR - Multiple Myeloma Clinical Trials
Role of Anti–CD38 Antibody Therapy in Induction and Maintenance in Newly Diagnosed Multiple Myeloma: How to Adopt in Clinical Practice
VA Committee
Frontline Therapy in Multiple Myeloma
Cancers | Free Full-Text | Pursuing a Curative Approach in Multiple Myeloma: A Review of New Therapeutic Strategies
The efficacy and safety of modified bortezomib‐lenalidomide‐dexamethasone in transplant‐eligible patients with newly diagnosed multiple myeloma - Okazuka - 2020 - European Journal of Haematology - Wiley Online Library
Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Understanding the VRd Regimen for Newly Diagnosed Myeloma by International Myeloma Foundation - Issuu
Multiple Myeloma Tumor Board: Maintenance, Consolidation, and Continuous Therapy (Transcript)
Combination Regimens for Multiple Myeloma Show Efficacy in the Transplant-Ineligible Population, According to Dingli
How I manage frontline transplant-ineligible multiple myeloma
Managing A Case of Newly-Diagnosed Transplant-Ineligible MM
Treating Frail and Transplant-Ineligible Patients With MM
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone - ScienceDirect
Treatment Considerations for Transplant-Ineligible Multiple Myeloma
Induction Therapy for Newly Diagnosed Multiple Myeloma
Lenalidomide, bortezomib and dexamethasone induction therapy for the treatment of newly diagnosed multiple myeloma: a practical review - McCaughan - 2022 - British Journal of Haematology - Wiley Online Library
Developments in Newly Diagnosed Multiple Myeloma: Considerations for Improved Patient Outcomes
Expert Guidance on Current Standards and New Directions in Newly Diagnosed Multiple Myeloma
Primary treatment of light-chain amyloidosis with bortezomib, lenalidomide, and dexamethasone. - Abstract - Europe PMC
Patient Case 3: Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Patient characteristics associated with dose modifications for VRd among newly diagnosed multiple myeloma patients | Future Oncology
Current approaches to management of newly diagnosed multiple myeloma - Goel - 2022 - American Journal of Hematology - Wiley Online Library
(PDF) Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma
VRd Lite 療法
